|Bid||1.0600 x 1300|
|Ask||1.0700 x 1000|
|Day's range||0.9800 - 1.0600|
|52-week range||0.9660 - 14.5500|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||N/A|
|Earnings date||14 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||2.00|
CHICAGO, November 14, 2022--Exicure reported financial results for the quarter ended September 30, 2022 and provided an update on its business strategy and corporate progress.
CHICAGO, September 26, 2022--Exicure announced plans to restructure the Company and align resources to continue exploring strategic alternatives that maximize stockholder value.
CHICAGO, September 01, 2022--Exicure CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference.